Fagron announces the completion of Purifarma

Core Insights - Fagron has successfully completed the acquisition of Purifarma in Brazil, marking a significant step in its M&A strategy and enhancing its scalable platform for long-term growth [1][2][3] Group 1: Acquisition Details - The acquisition of Purifarma, valued at approximately R$250 million, is expected to provide procurement benefits in Latin America and across Fagron's global operations [2] - Purifarma is recognized as a large-scale Essentials business with a competitive product portfolio and significant volumes, which will allow Fagron to improve its product mix and extend its reach to industrial clients [2][3] Group 2: Strategic Commentary - CEO Rafael Padilla emphasized that the completion of this acquisition strengthens Fagron's position in Brazil and aligns with its disciplined buy-and-build strategy, focusing on scale, procurement, and access to industrial clients [3] - The company aims to remain selective and execution-focused during the integration of Purifarma to build a larger and more efficient platform [3] Group 3: Company Overview - Fagron is a leading global company in pharmaceutical compounding, delivering personalized medicine to various healthcare providers in over 35 countries [5] - The company is headquartered in Nazareth, Belgium, and operates through its Dutch subsidiary, Fagron BV, which is based in Rotterdam [6]